ADU-S100 administered as monotherapy had a significant effect on release of CXCL1, IFN-β, IFN-γ, and TNF-α, but only intratumorally not systemically, which could explain the slightly reduced abscopal anti-tumor effects seen in mice treated with ADU-S100 alone. Here, CXCL1 is linked to neoplasm.